ArriVent BioPharma Inc (AVBP) Actualités

Form 8-K/A - Current report: [Amend]

Form 8-K/A - Current report: [Amend]

Form 8-K - Current report

ArriVent Announces a Multi-Target ADC Collaboration with Alphamab

Collaboration will leverage Alphamab’s antibody drug conjugate (“ADC”) research and discovery platform and...

Form 8-K - Current report

ArriVent Appoints John Hohneker, M.D., to its Board of Directors

NEWTON SQUARE, Pa., May 16, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc., a clinical-stage company...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

ArriVent BioPharma Reports First Quarter 2024 Financial Results

Presented preclinical firmonertinib (formerly furmonertinib) data at the 2024 American Association for Cancer...

ArriVent Appoints Kristine Peterson to its Board of Directors

NEWTON SQUARE, Pa., April 22, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc., a clinical-stage company...

ArriVent BioPharma Reports Full Year 2023 Financial Results

Company progresses the development of furmonertinib with a data readout planned for 2024Furmonertinib granted...